Contributors
Recent Posts
- Healthcare Providers Must Remain Vigilant with ADA Service Animal Requirements
- The Ten Year Wait is Over: HRSA Releases 340B Dispute Resolution Final Rule
- HHS Final Rules Modernize the Stark Law and Anti-Kickback Statute to Usher in Value-Based Care
- The CDC’s New Definition of “Close Contact”: What You Need To Know
- U.S. Department of Labor Issues Revised Regulations Implementing FFCRA Leaves Following New York Court’s Decision
- Michigan Reinstitutes Pre-COVID Scope of Practice, Licensure, and Liability Standards
- DHHS Issues Terms and Conditions for Relief Funds
- Nursing Home Compliance Under the COVID-19 Microscope
- OCR Guidance During the COVID-19 Public Health Emergency
- Michigan Governor’s Executive Order 2020-30 Expands Health Care Professionals’ Scope of Practice and Lifts Certain Licensure Restrictions
Related Practices
- Adoption & Assisted Reproductive Technology
- Ambulatory Care Providers
- Bankruptcy, Insolvency & Creditors' Rights
- Bioethics & End-of-Life Care
- Biotechnology and Life Science
- Cannabis Law
- Government Investigations and Corporate Compliance
- Health Care
- Health Care Administrative Law & Regulatory Appeals
- HIPAA—Health Information Privacy & Security
- Hospitals and Health Care Systems
- Long-Term & Post-Acute Care Providers
- Nonprofits & Tax-Exempt Organizations
- Pharmacies, DEA & Robinson-Patman/340B Drug Programs
- Physicians, Dentists and Non-Physician Practitioners
Related Industries
Prescribers May Forego In-Person Medical Exam When Prescribing Controlled Substances via the Internet During COVID-19 Public Health Emergency
Under the federal Ryan Haight Act (the “Act”), prescribers must ordinarily perform an in-person medical evaluation of a patient before using the Internet to prescribe controlled substances for that patient. The Act contains an exception to the in-person evaluation requirement when prescribing is done via the “practice of telemedicine,” as defined in the Act. The Act’s definition of telemedicine includes the practice of medicine by means of an acceptable telecommunication system during a public health emergency declared by the Secretary of Health and Human Services (the “Secretary”), with the concurrence of the federal Attorney General through the Drug Enforcement Administration (“DEA”).
On January 31, 2020, the Secretary issued declared a public health emergency relating to the COVID-19 virus, existing nationwide since January 27, 2020. On Tuesday, March 17, 2020, the Office of Management and Budget approved the DEA’s guidance concerning telemedicine and the COVID-19 national health emergency. The DEA’s guidance can be found on the Diversion Control Division’s COVID-19 Information Page, located at: https://www.deadiversion.usdoj.gov/coronavirus.html. In short, the DEA has activated the exception in the Act for use of telemedicine to prescribe controlled substances during the COVID-19 national emergency, removing the need for an in-person medical evaluation prior to prescribing controlled substances via the Internet. This DEA guidance will remain in effect for so long as the Secretary’s designation of the national COVID-19 public health emergency remains in effect.
To sign up for Dykema’s Health Care Blog e-mail updates, please click here.